Bio‑Techne expanded its collaboration with Oxford Nanopore Technologies to develop and commercialize a broader portfolio of targeted enrichment kits for screening and diagnosing heritable genetic disorders. The extended agreement runs through 2032 and grants Bio‑Techne commercial rights beyond the initial carrier screening product. The partnership builds on the AmplideX Nanopore Carrier Plus Kit (long‑range PCR paired with nanopore reads), positioning both firms to push long‑read sequencing into clinical diagnostics. Asuragen’s CSO Brian Haynes and Oxford Nanopore’s Thomas Bray confirmed the focus on robust chemistry and coordinated product development ahead of AMP’s meeting in November.